Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis.
about
Recent advances in prenatal genetic screening and testingSpanish- and English-Speaking Pregnant Women's Views on cfDNA and Other Prenatal Screening: Practical and Ethical Reflections.What Do Parents of Children with Down Syndrome Think about Non-Invasive Prenatal Testing (NIPT)?Analysis of Down syndrome failed to be diagnosed after prenatal screening: A multicenter study.Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics.An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population.Positive Attitudes towards Non-Invasive Prenatal Testing (NIPT) in a Swedish Cohort of 1,003 Pregnant WomenObstetrician and Gynecologist Utilization of the Noninvasive Prenatal Testing Expanded Option.Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85 000 cases.Pre- and post-test genetic counseling for chromosomal and Mendelian disorders.Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing.Global perspectives on clinical adoption of NIPTPayer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.Fetal aneuploidy screening with cell-free DNA in late gestation.The clinical utility of genome-wide non invasive prenatal screening.Non-invasive prenatal screening versus prenatal diagnosis by array comparative genomic hybridization: a comparative retrospective study.Expanding non-invasive prenatal testing beyond chromosomes 21, 18, 13, X and Y.Noninvasive prenatal screening for fetal common sex chromosome aneuploidies from maternal blood.The benefits and limitations of cell-free DNA screening for 22q11.2 deletion syndrome.Cell-Free DNA Screening: Complexities and Challenges of Clinical Implementation.Changing to NIPT as a first-tier screening test and future perspectives: opinions of health professionals.Noninvasive prenatal testing for aneuploidy using cell-free DNA - New implications for maternal health.Survey of attitudes of Chinese perinatologists and obstetricians toward non-invasive prenatal genetic testing.Validation of combinatorial probe-anchor ligation-based sequencing as non-invasive prenatal test for trisomy at a central laboratory.QUAD versus cfDNA in an urban population in the second trimester for detection of trisomy 21: a cost sensitivity analysis.Recommended practice for laboratory reporting of non-invasive prenatal testing of trisomies 13, 18 and 21: a consensus opinion.Informed decision-making about prenatal cfDNA screening: An assessment of written materials.Obstetric professionals' perceptions of non-invasive prenatal testing for Down syndrome: clinical usefulness compared with existing tests and ethical implications.Impact of the increased adoption of prenatal cfDNA screening on non-profit patient advocacy organizations in the United States.False negative fetal cell free DNA screening for microdeletion syndromes in the presence of an unbalanced translocation involving monosomy 4p.Clinical experience with a single-nucleotide polymorphism-based non-invasive prenatal test for five clinically significant microdeletions.Decision outcomes in women offered noninvasive prenatal test (NIPT) for positive Down screening results.Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.Informative priors on fetal fraction increase power of the noninvasive prenatal screen.Non-invasive prenatal testing (NIPT): Europe's first multicenter post-market clinical follow-up study validating the quality in clinical routine.Comparison of first-tier cell-free DNA screening for common aneuploidies with conventional publically funded screening.Informed choice and decision making in women offered cell-free DNA prenatal genetic screening.Comment on "The clinical utility of genome-wide non invasive prenatal screening".Towards precision nephrology: the opportunities and challenges of genomic medicine.
P2860
Q28071888-B1DA70E1-E625-48DF-BD53-740A7CBDD296Q30197052-8284EF62-CC61-4461-B810-C116DCD81E83Q33634130-7837F802-2CCC-4E5E-BCE1-210A2C6FF3EAQ33818130-4090299C-9B12-43C3-81EB-CA91E0B0FA83Q34535626-3EAA98FE-B7C5-417B-B207-998957E6FE37Q35686965-DA6FEEB3-E83C-4714-BAC4-57AC49E3A8AAQ36022080-130CB216-9766-4308-AB21-C2074B1374C2Q36533915-EBAC19E6-0C5A-4F87-898D-EB79066C9C9FQ36762710-4BD0779A-0DD8-445D-9598-75A240D84323Q36784201-429F2E08-A06B-40C3-B1F0-63847385BA4CQ37067727-99531C92-47E6-4453-8623-7959C5653608Q37279297-64BE45B8-1039-4F82-9178-3A90C821DDB7Q37342219-789BADD0-0522-4BCB-ACD3-C771302A70ACQ37716310-075E2F63-CDB4-40F2-B078-23DFF89365CEQ38819938-64307556-C2E9-492C-A26F-0E11564A33F8Q38830275-7441C6E9-256B-46E3-951A-9A94D32267E8Q38838610-3ED85BC2-661D-414F-8B71-9C0101801008Q38860845-9249F65A-8F29-475C-945B-176B6775353CQ38867682-52CDEAF8-749F-498C-BB70-AB2506CE38A7Q38872392-B7571E65-66F2-4C1C-B7ED-34F1B9FDD1CDQ38928166-4A47F2E2-DA82-49E0-B44C-9783AF0F1330Q38959581-B5F4F521-2FA8-4807-B8B8-7029B2AC79C3Q39004076-C2A60049-E56C-4F4E-BC4D-F5668DAF2E1AQ39487915-7ACF7475-1F03-4E37-ABAF-E1B78FF0A37BQ39641895-D3FF4B92-7204-4C8D-9DB1-D21ADEFBED5AQ40413919-C2C762F8-F90E-4AEA-9333-EDCAA266B8D5Q41113357-D99F8120-4F98-4DB0-A11F-CA847178B57FQ41253896-CFEC1B69-6603-4F4E-98E3-B7C5B7464AB7Q41611034-B245FD72-9D0C-42B7-98BC-CA0B2C9A5044Q41829533-CECCB312-0645-4B75-8487-C16E7EDA8156Q45965934-D053149E-5B60-4BDD-9DF7-EA6B0C2304C9Q46081566-0BB2A47E-A9AB-491B-904F-50B6E477EF78Q47295754-0434E96D-0348-471E-95DA-4236EC89791AQ47296123-4F0A09B4-957A-4E6D-ACDB-3FC66E704B3FQ47366013-0041A15A-E25E-49D3-BD87-9B4304A56EFCQ48100099-1ABFC133-5820-462F-B38B-E3997D911302Q48110029-29AC7491-6C7A-4877-B2B3-EF753E88C8E6Q48126001-E3B0FBFF-9D79-4CFE-9759-7DE93AF493A5Q48150112-4DD227F8-8CA9-4D3A-9295-D071DCA170B2Q48171722-6451868B-7A73-4AD6-BF4E-F1F9B83B85B1
P2860
Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Position statement from the Ch ...... ociety for Prenatal Diagnosis.
@en
type
label
Position statement from the Ch ...... ociety for Prenatal Diagnosis.
@en
prefLabel
Position statement from the Ch ...... ociety for Prenatal Diagnosis.
@en
P2093
P2860
P356
P1433
P1476
Position statement from the Ch ...... Society for Prenatal Diagnosis
@en
P2093
Anthony Odibo
Brigitte Faas
Dave Wright
Howard Cuckle
Joann Johnson
Kevin Spencer
Lorraine Dugoff
Mary Norton
Peter Benn
Peter Schielen
P2860
P304
P356
10.1002/PD.4608
P577
2015-06-04T00:00:00Z